This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Steffel, J. Articles by Lüscher, T. F. Search for Related Content PubMed Articles by Steffel, J. Articles by Lüscher, T. F. Related Collections Risk Factors Developmental biology Other arteriosclerosis

(Circulation. 2009;119:919-921.)
© 2009 American Heart Association, Inc.

Editorial

Predicting the Development of Atherosclerosis

Jan Steffel, MD; Thomas F. Lüscher, MD

From the Department of Cardiology, CardioVascular Center, University Hospital, Zurich, and the Department of Cardiovascular Research, Institute of Physiology, University of Zurich, Switzerland.

Correspondence to Thomas F. Lüscher, MD, FRCP, FESC, Professor and Chairman of Cardiology and Head of Cardiovascular Research, University Hospital Zürich, Rämistrasse 100, CH-8091 Zürich, Switzerland. E-mail cardiotfl@gmx.ch

Key Words: Editorials • endothelial function • atherosclerosis • flow-mediated dilation

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Tis easy to see, hard to foresee.

— —Benjamin Franklin

Atherosclerotic vascular disease is one of the great epidemics of the 21st Century.¹ Decades before its clinical manifestation, endothelial dysfunction (ED) marks the beginning of an insidious disease process, which silently progresses to a point where it can only be slowed but not reversed. ED is induced by a variety of mediators, some of which are known and related to established cardiovascular risk factors such as smoking, dyslipidemia, hypertension, diabetes mellitus, and aging, whereas others are presently unknown. As ED develops, the balance between antiatherogenic and proatherogenic factors in slowly shifted in favor of the latter. In this multifactorial process, reduced bioavailability of nitric oxide (NO) plays a pivotal role. NO, a free radical gas with an in vivo half-life of a few seconds, is synthesized primarily from endothelial NO synthase (eNOS), which is activated in response to flow-induced shear stress, cytokines, and hormones.² In vitro, NO inhibits the expression of cell adhesion molecules such as VCAM-1, ICAM and E-selectin, as well as the secretion of proinflammatory cytokines such as interleukin 6 and interleukin 8, thus preventing monocyte attraction and adhesion.³ In line with these findings, early studies using eNOS knockout mice demonstrated an increase in atherosclerotic lesions in these animals.^4,5 In contrast, however, more recent studies revealed that eNOS knockout mice may under certain circumstances also be relatively protected from the development of atherosclerosis and that transgenic overexpression of eNOS in fact may accelerate atherogenesis.^6,7 Although the exact mechanism . . . [Full Text of this Article]